Welcome to our dedicated page for Korsana Biosciences SEC filings (Ticker: CYCN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Korsana Biosciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Korsana Biosciences's regulatory disclosures and financial reporting.
Cyclerion Therapeutics, Inc. (CYCN), which changed its name to Korsana Biosciences, Inc. at the merger effective time, reported the initial holdings of Jonathan Violin, its Chief Executive Officer, President and director. He holds 207,400 shares of common stock directly, including restricted shares received in the merger.
Violin also holds stock options to buy up to 1,048,244 shares of common stock at an exercise price of $4.15 per share expiring October 26, 2035, and options for 1,984,157 shares at $8.06 per share expiring June 29, 2036. A substantial portion of his stock and options vests in equal monthly installments through 2029 and 2030, subject to continued service.
Cyclerion Therapeutics, Inc. (CYCN), now named Korsana Biosciences, Inc., reported the initial equity holdings of Chief Medical Officer Matthew James Leoni on a Form 3 following its merger with Pre-Merger Korsana Biosciences, Inc. effective September 8, 2026.
Leoni holds two stock option awards to buy common stock that were received in exchange for options of Pre-Merger Korsana. One option covers 253,415 shares at an exercise price of $7.48 per share, expiring on June 7, 2036, and is scheduled to vest 25% on June 8, 2027 with monthly vesting thereafter through June 8, 2030. The other covers 394,314 shares at an exercise price of $8.06 per share, expiring on June 29, 2036, vesting 25% on June 18, 2027 with monthly vesting thereafter through June 18, 2030, in each case subject to his continued service.
Cyclerion Therapeutics, Inc. (symbol CYCN), now renamed Korsana Biosciences, Inc. at the merger "Effective Time," reports director Michelle Patricia Pernice as a new insider and discloses her derivative holdings. She holds a stock option to acquire 28,805 shares of common stock at an exercise price of $4.15 per share, expiring October 26, 2035.
The option was received in the merger in exchange for options of pre‑merger Korsana Biosciences and vested as to 25% on November 8, 2025, with the remainder vesting in equal monthly installments through November 8, 2028, subject to her continued service.
Cyclerion Therapeutics, Inc. (CYCN), now named Korsana Biosciences, Inc., reported initial insider holdings for director Heidi Henson. She holds a stock option giving her the right to buy 100,994 shares of common stock at an exercise price of $8.06 per share, expiring June 29, 2036. These options were received in connection with the merger in which the former Korsana Biosciences, Inc. became a wholly owned subsidiary and Cyclerion changed its name to Korsana Biosciences, Inc. The option vests in 36 equal monthly installments from June 18, 2026 through June 18, 2029, subject to her continued service.
Cyclerion Therapeutics, Inc. (CYCN) filed an initial statement of beneficial ownership on Form 3 for Andrew Gottesdiener, identifying him as a director of the company. The filing reports no equity holdings or derivative positions and discloses no transactions in Cyclerion securities.
Cyclerion Therapeutics, Inc. (CYCN), now named Korsana Biosciences, Inc., received an initial ownership report on Form 3 from Fairmount Funds Management LLC and related investment funds and managers. The filing lists their indirect holdings following the merger in which Pre-Merger Korsana became a subsidiary and Cyclerion adopted the Korsana Biosciences, Inc. name.
The Fairmount-affiliated funds report indirect ownership of 6,911,174 shares of common stock through Fairmount Healthcare Fund II L.P. and 2,192,555 shares of common stock through Fairmount Healthcare Co-Invest VI L.P., plus derivatives: Series B Non-Voting Preferred Stock convertible into 2,074,000 common shares and 66,436 pre-funded warrants with a $0.0001 exercise price. The preferred stock and warrants are subject to beneficial ownership limits generally capped at 19.99% of outstanding common stock. Fairmount, Peter Harwin and Tomas Kiselak disclaim beneficial ownership beyond their pecuniary interests.
Cyclerion Therapeutics, Inc. (CYCN), which changed its name to Korsana Biosciences, Inc. at the merger effective time, reported the initial holdings of director Nimish P. Shah on a Form 3. The filing shows indirect interests in 4,549,585 shares of common stock, plus derivative positions convertible or exercisable into an additional 1,908,000 shares via Series B Non-Voting Preferred Stock and 3,305,044 shares via pre-funded warrants. The Venrock-affiliated funds have elected 9.99% beneficial ownership limitations (resettable up to 19.99% after a 61-day notice), and Shah disclaims beneficial ownership beyond his indirect pecuniary interests.
Cyclerion Therapeutics, Inc. (symbol CYCN), now renamed Korsana Biosciences, Inc. after a two-step merger completed on September 8, 2026, reports the initial beneficial ownership of its Chief Financial Officer, Mark J. Vignola, on a Form 3. His holdings consist of stock options received in the merger in exchange for options of pre-merger Korsana.
Vignola holds options covering 253,415 shares of common stock at an exercise price of $4.15 per share, expiring March 8, 2036, vesting 25% on March 6, 2027 with monthly vesting through March 6, 2030, and additional options covering 394,314 shares at $8.06 per share, expiring June 29, 2036, vesting 25% on June 18, 2027 with monthly vesting through June 18, 2030, in each case subject to his continued service.
Cyclerion Therapeutics, Inc. (CYCN) reported the results of its August 26, 2026 shareholder meeting held in connection with its pending merger with Korsana Biosciences, Inc. Shareholders approved the Nasdaq stock issuance for the merger, an increase in authorized common shares from 400,000,000 to 700,000,000, and a reverse stock split.
The board, with Korsana’s agreement, set the reverse stock split ratio at 1-for-7, which is expected to reduce outstanding common shares from approximately 4.7 million to approximately 0.7 million, while leaving the authorized share count unchanged apart from the approved increase. Fractional shares will be settled in cash based on the Nasdaq closing price on the amendment filing date, and outstanding equity awards and plan share reserves will be adjusted proportionately.
Shareholders also elected six directors, ratified Ernst & Young LLP as auditor for 2026, and approved new 2026 stock incentive and employee stock purchase plans and advisory votes on executive compensation. A proposal to redomesticate to the Cayman Islands was not approved, so the combined company will remain a Massachusetts corporation. Following the reverse split and merger, the combined company’s stock is expected to trade on Nasdaq under the name “Korsana Biosciences, Inc.” and ticker “KRSA” beginning September 9, 2026.
Cyclerion Therapeutics, Inc. (CYCN) announced that its board of directors has set the close of business on September 4, 2026 as the record date for a previously announced distribution of contingent value rights (CVRs). The CVR distribution will be made to holders of record of Cyclerion’s common stock and Series A Preferred Stock in connection with its planned merger with Korsana Biosciences, Inc.. The company also outlines numerous risks and uncertainties that could affect the completion and timing of the merger, the CVR distribution, and any potential payments under the CVRs, and directs investors to review the Form S-4 and proxy statement/prospectus filed with the SEC for detailed information.